Vivus diet drug approval decision delayed 3 months
April 9 (Reuters) - U.S. health regulators have extended by three months their deadline for making an approval decision on Vivus Inc's diet drug Qnexa, the company said on Monday, marking the latest delay to bring a new obesity treatment to market.
The Food and Drug Administration informed Vivus that it will decide whether to approve Qnexa by July 17 as it needs more time to review the company's risk evaluation plan for the drug. The previous FDA action date for Qnexa had been April 17.
Vivus's Qnexa is one of three experimental new weight loss drugs seeking FDA approval after initial rejections by the agency.
- White House reverses, says Obama met uncle and lived with him during law school
- Flights delayed as air pollution hits record in Shanghai
- South Africa mourns Mandela, will bury him on December 15 |
- French launch Central African Republic mission but deaths mount
- Supreme Court to decide on patent protections for software